Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2017-05-22 | Dr. Christopher Pleister, 69 Director (nonexecutive) of Depfa Bank plc. (since 2015), Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) since November 2016 (member since 2015). He is the former Chairman of FMSA (German financial market stabilization agency) (2011-2014) and board member 2009-2011), and former Chairman of the Supervisory Board of Deutsche Zentral-Gennossenschaftsbank Frankfurt (2000-2008), former Chairman of BVR (federal association of German cooperative banks) (2000-2008) and Director of Deutsche Gennossenschaftsbank (1990-1999). |
| 2018-05-09 | Dr. Christopher Pleister, 69, Director (nonexecutive) of Depfa Bank plc ... Continuing Class I Director for CEE since 2016, Continuing Class II Director for EEA since 2016, Continuing Class II Director for GF since 2016 ... The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister ... The Advisory Committee, currently comprising Ambassador Burt and Mr. Dostmann (Chair) and Dr. Pleister ... The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister ... The following table sets forth the aggregate compensation ... Dr. Pleister: $7,303 (CEE), $4,821 (EEA), $17,517 (GF), total $29,641. |
| 2019-05-20 | Dr. Christopher Pleister, 71 Director (nonexecutive) of Depfa Bank plc... Nominee as Class I Director for CEE to serve until 2022 Nominee as Class II Director for EEA to serve until 2022 Continuing Class II Director for GF since 2016... The Audit Committee, currently comprising Dr. Pleister... The Advisory Committee, currently comprising Dr. Pleister... The Nominating and Governance Committee, currently comprising Dr. Pleister... Compensation: $15,179 from EEA, $7,525 from GF, total $52,103 from Fund Complex. |
| 2020-05-15 | Dr. Christopher Pleister, 72 Director (nonexecutive) of Depfa Bank plc. (since 2015), Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) since November 2016 (member since 2015). He is the former Chairman of FMSA (German financial market stabilization agency) (2011-2014). The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister. The Advisory Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), Dr. Pleister and Mr. Zügel. The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister. The following table sets forth (a) the aggregate compensation from each Fund for the fiscal year ended October 31, 2019 for CEE and December 31, 2019 for GF, and (b) the total compensation from the Fund Complex for the 2019 calendar year, (i) for each Director who is not an interested person of the Funds, and (ii) for all such Directors as a group. Dr. Christopher Pleister $17,072 $ 18,176 $ 40,693 |
| 2021-05-14 | Dr. Christopher Pleister, 73 Director (nonexecutive) of Depfa Bank plc. (since 2015)... Director of The European Equity Fund, Inc. (since 2016) Continuing Class I Director for CEE since 2016 Continuing Class II Director for GF since 2016 Lead Independent Director Shares of Common Stock Owned at April 30, 2021: CEE: 393, GF: 808 Audit Committee, Advisory Committee, Nominating and Governance Committee Aggregate Compensation from Fund Complex: $54,503 |
| 2022-05-13 | Dr. Christopher Pleister, 74 Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) since 2016 (member since 2015). He is the former Chairman of FMSA (German financial market stabilization agency) (2011-2014) and Director (nonexecutive) of Depfa Bank plc. (2015-2021) Director of The European Equity Fund, Inc. (since 2016) Nominee as Class I Director for CEE to serve until the 2025 Annual Meeting. Class I Director for CEE since 2016 Continuing Class II Director for GF since 2016 CEE: 410 GF: 1,162 Annual compensation: $58,003 Committees: Audit Committee, Advisory Committee, Nominating and Governance Committee |
| 2023-05-12 | Dr. Christopher Pleister, 75 Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) (since 2016) (member since 2015). Formerly, Chairman of FMSA (German financial market stabilization agency) (2011-2014) and Director (nonexecutive) of Depfa Bank plc. (2015-2021) ... Continuing Class I Director for CEE since 2016 Retiring as a Class II Director for GF at the Annual Meeting ... The Audit Committee, currently comprising Mr. Dostmann (Chair), Ms. Flannery and Dr. Pleister ... The Advisory Committee, currently comprising Mr. Dostmann (Chair), Dr. Hatje, Mr. Koepp, Dr. Pleister and Mr. Zügel ... The Nominating and Governance Committee, currently comprising Dr. Pleister (Chair), Ms. Flannery and Mr. Zügel ... The Audit Committee of CEE met five times during CEE’s past fiscal year and the Audit Committee of GF met four times during GF’s Fund’s past fiscal year. |
| Filing Date | Source Excerpt |
|---|---|
| 2017-05-22 | Dr. Christopher Pleister, 69 Director (nonexecutive) of Depfa Bank plc. (since 2015), Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) since November 2016 (member since 2015). He is the former Chairman of FMSA (German financial market stabilization agency) (2011-2014) and board member 2009-2011), and former Chairman of the Supervisory Board of Deutsche Zentral-Gennossenschaftsbank Frankfurt (2000-2008), former Chairman of BVR (federal association of German cooperative banks) (2000-2008) and Director of Deutsche Gennossenschaftsbank (1990-1999). Nominee as Class I Director for CEE to serve until 2019 Annual Meeting; Class II Director since 2016 Nominee as Class II Director for EEA to serve until 2019 Annual Meeting; Class II Director since 2016 Nominee as Class II Director for GF to serve until 2020 Annual Meeting; Class III Director since 2016 The Advisory Committee, currently comprising Messrs. Bierbaum, Dostmann (Chair), Goeltz and Pleister, makes recommendations to the full Board with respect to the Administration Agreement between each Fund and Deutsche Investment Management Americas Inc., and the Investment Advisory Agreement between each Fund and Deutsche Asset Management International GmbH. The Advisory Committee met two times during each Funds past fiscal year. The Audit Committee, currently comprising Ambassador Burt, Messrs. Dostmann, Goeltz (Chair) and Pleister, operates pursuant to a written charter which is available on the Funds website, deutschefunds.com/EN/docs/products/Germany-Funds-Audit-Committee-Charter.pdf. The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair), Messrs. Goeltz (Chair) and Pleister, operates pursuant to a written charter which is available on the Funds website, deutschefunds.com/EN/docs/products/Germany-Master-Nominating-Committee-Charter.pdf. The following table sets forth (a) the aggregate compensation from each Fund for the fiscal year ended October 31, 2016 for CEE and December 31, 2016 for EEA and GF, and (b) the total compensation from the Fund Complex for the 2016 calendar year, (i) for each Director who is not an interested person of the Funds, and (ii) for all such Directors as a group. Dr. Christopher Pleister $1,136 from EEA $3,886 from GF Total $5,022 from Fund Complex. |
| 2018-05-09 | Dr. Christopher Pleister, 69 Director (nonexecutive) of Depfa Bank plc. (since 2015), Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) since November 2016 (member since 2015). He is the former Chairman of FMSA (German financial market stabilization agency) (2011-2014) and board member 2009-2011), and former Chairman of the Supervisory Board of Deutsche Zentral-Gennossenschaftsbank Frankfurt (2000-2008), former Chairman of BVR (federal association of German cooperative banks) (2000-2008) and Director of Deutsche Gennossenschaftsbank (1990-1999). The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister, operates pursuant to a written charter which is available on the Funds' website. The Audit Committee's organization and responsibilities are contained in the Audit Committee Report, which is included in this Proxy Statement, and in its written charter. The members of the Audit Committee are "independent" as required by the independence standards of Rule 10A-3 under the Securities Exchange Act of 1934. The Advisory Committee, currently comprising Ambassador Burt and Mr. Dostmann (Chair) and Dr. Pleister, makes recommendations to the full Board with respect to the Administration Agreement between each Fund and Deutsche Investment Management Americas Inc., and the Investment Advisory Agreement between each Fund and Deutsche Asset Management International GmbH. The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister, operates pursuant to a written charter which is available on the Funds' website. The Board has determined that each of the members of the Nominating and Governance Committee is not an "interested person" as the term is defined in Section 2(a)(19) of the Investment Company Act. The following table sets forth (a) the aggregate compensation from each Fund for the fiscal year ended October 31, 2017 for CEE and December 31, 2017 for EEA and GF, and (b) the total compensation from the Fund Complex for the 2017 calendar year, (i) for each Director who is not an interested person of the Funds, and (ii) for all such Directors as a group. Dr. Christopher Pleister CEE: $7,303 EEA: $4,821 GF: $17,517 Total: $29,641 All members on each of the five committees of the Board are not "interested persons" as the term is defined in the Investment Company Act, with the exception of Mr. Strenger, who is a member of the Executive Committee and Dr. Leoni, who is a member of the Executive Committee and Valuation Committee. |
| 2019-05-20 | Dr. Christopher Pleister, 71 Director (nonexecutive) of Depfa Bank plc. (since 2015), Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) since November 2016 (member since 2015). He is the former Chairman of FMSA (German financial market stabilization agency) (2011-2014) and board member 2009-2011), and former Chairman of the Supervisory Board of Deutsche Zentral-Gennossenschaftsbank Frankfurt (2000-2008), former Chairman of BVR (federal association of German cooperative banks) (2000-2008) and Director of Deutsche Gennossenschaftsbank (1990-1999). Nominee as Class I Director for CEE to serve until the 2022 Annual Meeting. Class I Director for CEE since 2016 Nominee as Class II Director for EEA to serve until the 2022 Annual Meeting. Class II Directors for EEA since 2016 Continuing Class II Director for GF since 2016 The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister, operates pursuant to a written charter which is available on the Funds' website. The Advisory Committee, currently comprising Ambassador Burt and Mr. Dostmann (Chair) and Dr. Pleister, makes recommendations to the full Board with respect to the Administration Agreement between each Fund and DWS Investment Management Americas, Inc., and the Investment Advisory Agreement between each Fund and DWS International GmbH. The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister, operates pursuant to a written charter which is available on the Funds' website. The following table sets forth (a) the aggregate compensation from each Fund for the fiscal year ended October 31, 2018 for CEE and December 31, 2018 for EEA and GF, and (b) the total compensation from the Fund Complex for the 2018 calendar year, (i) for each Director who is not an interested person of the Funds, and (ii) for all such Directors as a group. Dr. Christopher Pleister $ 15,179 $ 7,525 $ 29,399 $ 52,103 No compensation is paid by a Fund to Directors who are interested persons of the Fund or of any entity of the Deutsche Bank Group or to officers. |
| 2020-05-15 | The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister... The Advisory Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), Dr. Pleister and Mr. Zügel... The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister... Dr. Christopher Pleister, an Independent Director and member of the Advisory Committee, the Audit Committee and the Nominating and Governance Committee, serves as Lead Independent Director... The following table sets forth (a) the aggregate compensation from the Fund for the fiscal year ended December 31, 2019... Dr. Christopher Pleister $5,445. |
| 2021-05-14 | The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister... The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister... The Advisory Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), Dr. Hatje, Dr. Pleister and Mr. Zügel... The following table sets forth (a) the aggregate compensation from the Fund for the fiscal year ended December 31, 2020... Dr. Christopher Pleister $9,106. |
| 2022-05-13 | Dr. Christopher Pleister, 74 Chairman of the Appeal Panel of the Single Resolution Board... Director of The Central and Eastern Europe Fund, Inc. (since 2016) Director of The New Germany Fund, Inc. (since 2016) Nominee for Class II Director to serve until the 2025 Annual Meeting. Class II Director since 2016... The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and and Dr. Pleister... The Advisory Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), Dr. Hatje, Dr. Pleister and Mr. Zügel... The Nominating and Governance Committee, currently comprising Ambassador Burt (Chair), Dr. Pleister and Mr. Zügel... Dr. Christopher Pleister, an Independent Director and member of the Advisory Committee, the Audit Committee and the Nominating and Governance Committee, serves as Lead Independent Director for the Fund. |
| 2023-05-12 | Dr. Christopher Pleister, 75 Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) (since 2016) (member since 2015). Formerly, Chairman of FMSA (German financial market stabilization agency) (2011-2014) and Director (nonexecutive) of Depfa Bank plc. (2015-2021) Continuing Class II Director since 2016 Dr. Christopher Pleister, an Independent Director and member of the Advisory Committee, the Audit Committee and the Nominating and Governance Committee, serves as Lead Independent Director for the Fund and as such is available to act as liaison between the Independent Directors and management and to consult with the Chairman to the extent deemed appropriate. The Fund pays each of its Directors who is not an interested person of the Fund, of the Investment Adviser or of the Administrator an annual fee of $8,000 plus $1,167 for each Board meeting and $917 for each Committee meeting attended ($500 for attendance at Advisory Committee meetings for Directors who are not members of the Committee). The Fund reimburses the Directors (except for those employed by the DWS Group) for travel expenses in connection with Board meetings. The Chairman of the Audit Committee, Advisory Committee, and Nominating and Governance Committee each receives an additional annual retainer of $4,000, $3,000 and $3,000, respectively. The Lead Independent Director also receives an additional annual retainer of $2,000. The following table sets forth (a) the aggregate compensation from the Fund for the fiscal year ended December 31, 2022, and (b) the total compensation from the Fund Complex for the 2022 calendar year, (i) for each Director who is not an interested person of the Fund, and (ii) for all such Directors as a group. Name of Director Aggregate Compensation from Fund Total Compensation from Fund Complex Dr. Christopher Pleister $11,633 $65,922 No compensation is paid by the Fund to Directors who are interested persons of the Fund or of any entity of the DWS Group or to officers. |
| Filing Date | Source Excerpt |
|---|---|
| 2017-05-22 | Dr. Christopher Pleister, 69 Director (nonexecutive) of Depfa Bank plc. (since 2015), Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) since November 2016 (member since 2015). He is the former Chairman of FMSA (German financial market stabilization agency) (2011-2014) and board member 2009-2011), and former Chairman of the Supervisory Board of Deutsche Zentral-Gennossenschaftsbank Frankfurt (2000-2008), former Chairman of BVR (federal association of German cooperative banks) (2000-2008) and Director of Deutsche Gennossenschaftsbank (1990-1999). |
| 2018-05-09 | Dr. Christopher Pleister, 69 Director (nonexecutive) of Depfa Bank plc. (since 2015), Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) since November 2016 (member since 2015). He is the former Chairman of FMSA (German financial market stabilization agency) (2011-2014) and board member 2009-2011), and former Chairman of the Supervisory Board of Deutsche Zentral-Gennossenschaftsbank Frankfurt (2000-2008), former Chairman of BVR (federal association of German cooperative banks) (2000-2008) and Director of Deutsche Gennossenschaftsbank (1990-1999). Continuing Class I Director for CEE since 2016 Continuing Class II Director for EEA since 2016 Continuing Class II Director for GF since 2016 CEE: 0 EEA: 0 GF: 0 The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister, operates pursuant to a written charter which is available on the Funds' website. The Advisory Committee, currently comprising Ambassador Burt and Mr. Dostmann (Chair) and Dr. Pleister, makes recommendations to the full Board with respect to the Administration Agreement between each Fund and Deutsche Investment Management Americas Inc., and the Investment Advisory Agreement between each Fund and Deutsche Asset Management International GmbH. The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister, operates pursuant to a written charter which is available on the Funds' website. The following table sets forth (a) the aggregate compensation from each Fund for the fiscal year ended October 31, 2017 for CEE and December 31, 2017 for EEA and GF, and (b) the total compensation from the Fund Complex for the 2017 calendar year, (i) for each Director who is not an interested person of the Funds, and (ii) for all such Directors as a group. Dr. Christopher Pleister 7,303 4,821 17,517 29,641 |
| 2019-05-20 | Dr. Christopher Pleister, 71 Director (nonexecutive) of Depfa Bank plc. (since 2015), Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) since November 2016 (member since 2015). He is the former Chairman of FMSA (German financial market stabilization agency) (2011-2014) and board member 2009-2011), and former Chairman of the Supervisory Board of Deutsche Zentral-Gennossenschaftsbank Frankfurt (2000-2008), former Chairman of BVR (federal association of German cooperative banks) (2000-2008) and Director of Deutsche Gennossenschaftsbank (1990-1999). Nominee as Class I Director for CEE to serve until the 2022 Annual Meeting. Class I Director for CEE since 2016 Nominee as Class II Director for EEA to serve until the 2022 Annual Meeting. Class II Directors for EEA since 2016 Continuing Class II Director for GF since 2016 CEE: 0 EEA: 311 GF: 194 The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister, operates pursuant to a written charter which is available on the Funds website, https://fundsus.dws.com/EN/docs/products/Germany-Funds-Audit-Committee-Charter.pdf. The Audit Committees organization and responsibilities are contained in the Audit Committee Report, which is included in this Proxy Statement, and in its written charter. The members of the Audit Committee are 3independent 4 as required by the independence standards of Rule 10A-3 under the Securities Exchange Act of 1934. The Board of Directors has determined that each member of the Audit Committee is financially literate and has determined that Mr. Dostmann and Dr. Froewiss meet the requirements for an audit committee financial expert under the rules of the Securities and Exchange Commission ( 3EC 4). Although the Board has determined that Mr. Dostmann and Dr. Froewiss meet the requirements for an audit committee financial expert, their responsibilities are the same as those of the other audit committee members. Mr. Dostmann and Dr. Froewiss are not auditors or accountants, do not perform 3field work 4 and are not full-time employees. The SEC has stated: (i) that an audit committee member who is designated as an audit committee financial expert will not be deemed to be an 3expert 4 for any purpose as a result of being identified as an audit committee financial expert; and (ii) that the designation or identification of a person as an audit committee financial expert does not: (A) impose on such person any duties, obligations, or liabilities that are greater than those imposed on such persons as members of the audit committee or board of directors in the absence of such designation or identification; or (B) affect the duties, obligations, or liability of any other member of the audit committee or the board of directors. The Audit Committee met four times during each Funds fiscal year ending in 2018. The Advisory Committee, currently comprising Ambassador Burt and Mr. Dostmann (Chair) and Dr. Pleister, makes recommendations to the full Board with respect to the Administration Agreement between each Fund and DWS Investment Management Americas, Inc., and the Investment Advisory Agreement between each Fund and DWS International GmbH. The Advisory Committee met two times during each Funds past fiscal year. The Executive Committee, currently comprising Ambassador Burt and Dr. Leoni and Mr. Strenger, has the authority to act for the Board on all matters between meetings of the Board subject to any limitations under applicable state law. The Executive Committee did not meet during each Funds past fiscal year. The Valuation Committee, currently comprising Drs. Bender and Leoni (Chair), reviews each Funds valuation procedures and makes recommendations with respect thereto and, to the extent required by such procedures, determines the fair value of the Funds securities or other assets. The Valuation Committee met two times during each Funds past fiscal year. The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister, operates pursuant to a written charter which is available on the Funds website, https://fundsus.dws.com/EN/docs/products/Germany-Master-Nominating-Committee-Charter.pdf. The Board has determined that each of the members of the Nominating and Governance Committee is not an 3interested person 4 as the term is defined in Section 2(a)(19) of the Investment Company Act. Generally, the Nominating and Governance Committee identifies, evaluates and selects and nominates, or recommends to the Board of Directors, candidates for the Board or any committee of the Board, and also advises the Board regarding governance matters generally and confirms that the Board and Audit Committee undertake annual self-evaluations. To be eligible for nomination as a Director a person must, at the time of such persons nomination, have Relevant Experience and Country Knowledge and must not have any Conflict of Interest, as those terms are defined in the Funds Bylaws. The relevant portions of each Funds Bylaws describing these requirements are included as Annex A. The Nominating and Governance Committee may also take into account additional factors listed in the Nominating and Governance Committee Charter, which generally relate to the nominees industry knowledge, business experience, education, ethical reputation, special skills, ability to work well in group settings and the ability to qualify as an 3independent director 4. When assessing a candidate for nomination, the Nominating and Governance Committee considers whether the individuals background, skills and experience will complement the background, skills and experience of other nominees and will contribute to the diversity of the Board. The Nominating and Governance Committee met two times during each Funds past fiscal year. The following table sets forth the aggregate compensation from each Fund for the fiscal year ended October 31, 2018 for CEE and December 31, 2018 for EEA and GF, and the total compensation from the Fund Complex for the 2018 calendar year, for each Director who is not an interested person of the Funds, and for all such Directors as a group. Dr. Christopher Pleister $ 15,179 $ 7,525 $ 29,399 $ 52,103 |
| 2020-05-15 | Dr. Christopher Pleister, 72 Director (nonexecutive) of Depfa Bank plc. (since 2015)... Continuing Class I Director for CEE since 2016 Nominee as Class II Director for GF to serve until the 2023 Annual Meeting. Class II Director for GF since 2016 The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister... The Advisory Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), Dr. Pleister and Mr. Zügel... The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister... CEE Aggregate Compensation from Fund: $17,072 |
| 2021-05-14 | Dr. Christopher Pleister, 73 Director (nonexecutive) of Depfa Bank plc. (since 2015)... Director of The European Equity Fund, Inc. (since 2016) Continuing Class I Director for CEE since 2016 Continuing Class II Director for GF since 2016 Audit Committee, Nominating and Governance Committee, Advisory Committee Lead Independent Director Shares: CEE 393, GF 808 Compensation: GF $33,362 + CEE $19,355 = $54,503 |
| 2022-05-13 | Dr. Christopher Pleister, 74 Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) since 2016... Director of The European Equity Fund, Inc. (since 2016) Nominee as Class I Director for CEE to serve until the 2025 Annual Meeting. Class I Director for CEE since 2016 Continuing Class II Director for GF since 2016 The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Dr. Pleister... The Advisory Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), Dr. Hatje, Dr. Pleister and Mr. Zügel... The Nominating and Governance Committee, currently comprising Ambassador Burt (Chair), Dr. Pleister and Mr. Zügel... The following table sets forth (a) the aggregate compensation from each Fund for the fiscal year ended October 31, 2021 for CEE and December 31, 2021 for GF, and (b) the total compensation from the Fund Complex for the 2021 calendar year, (i) for each Director who is not an interested person of the Funds, and (ii) for all such Directors as a group. Dr. Christopher Pleister CEE: $18,988 GF: $31,124 Total: $58,003 |
| 2023-05-12 | Dr. Christopher Pleister, 75 Chairman of the Appeal Panel of the Single Resolution Board (Institution of the European Banking Union) (since 2016) (member since 2015). Formerly, Chairman of FMSA (German financial market stabilization agency) (2011-2014) and Director (nonexecutive) of Depfa Bank plc. (2015-2021) ... Continuing Class I Director for CEE since 2016 Retiring as a Class II Director for GF at the Annual Meeting ... The Audit Committee, currently comprising Mr. Dostmann (Chair), Ms. Flannery and Dr. Pleister ... The Nominating and Governance Committee, currently comprising Dr. Pleister (Chair), Ms. Flannery and Mr. Zügel ... The Advisory Committee, currently comprising Mr. Dostmann (Chair), Dr. Hatje, Mr. Koepp, Dr. Pleister and Mr. Zügel ... The Audit Committee of CEE met five times during CEE’s past fiscal year and the Audit Committee of GF met four times during GF’s Fund’s past fiscal year. |
Data sourced from SEC filings. Last updated: 2025-12-06